KB-1202

Girentuximab

×
Please enable JavaScript in your browser to complete this form.
52672
Home » Girentuximab

Background of Girentuximab

Girentuximab is a humanized monoclonal antibody that specifically targets CAIX, a protein highly expressed in renal cell carcinoma but expressed at low levels in normal tissues. By binding to CAIX, Girentuximab can recognize and attack tumor cells, inhibiting their growth and spread. The mechanism of action of Girentuximab primarily involves direct inhibition of tumor cell proliferation and induction of immune responses. It can block tumor cell growth signaling by binding to CAIX and induce cell apoptosis. In addition, Girentuximab can activate the immune system, promoting immune clearance of tumor cells.

Specifications

Catalog NumberKB-1202
Antibody NameGirentuximab
IsotypeHuman IgG1,kappa
FC MuationsWild Type
TargetCAIX
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationFACS
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Constantijn H J ,Muselaers, Alexander B ,et al.Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.[J].Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.DOI:10.2967/jnumed.114.137356.
  2. Divgi C R , Uzzo R G , Gatsonis C ,et al.Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial[J].Journal of Clinical Oncology, 2013.DOI:10.1200/jco.2011.41.2445.
Please enable JavaScript in your browser to complete this form.